Year 2019 / Volume 111 / Number 10
Review
Barrett’s esophagus: “All diseases are divine and all are human”

789-794

DOI: 10.17235/reed.2019.6261/2019

Vicente Munitiz Ruiz, Luisa F. Martienz de Haro, Ángeles Ortiz, David Ruiz de Angulo, Pascual Parrilla,

Abstract
Barrett’s esophagus (BE) is a controversial condition. The significance of this condition lies in its premalignant potential, so it is important that clinically applicable biomarkers be identified for early detection and targeted prevention. Dysplasia is currently used as main biomarker, but others most recently surveyed in cancer also include microRNAs. Classically, BE was considered to be an acquired disease related to pathological gastroesophageal acid and bile reflux. However, some cases are associated with genetic predisposition, representing an inherited, familial form of BE. The actual gene, or genes, involved in this condition have not yet been identified. Main therapeutic options include medical treatment and antireflux surgery. Both types of treatment are equally efficient in controlling symptoms and neither is able to cause the metaplastic segment to disappear, which is why the risk of malignancy remains. However, we may use endoscopic radiofrequency to eradicate BE and replace it by the typical squamous epithelium of the esophagus. The currently accepted indications of radiofrequency in BE include low- and high-grade dysplasia, but not Barrett’s esophagus without dysplasia. In conclusion, BE may have two different presentations: environmental (“human”, reflux) or sporadic BE, which is the most common form, and genetic (“divine”, inherited) or familiar BE, less common but with a greater risk for malignancy. As they might be two different diseases, surveillance programs and treatments should also be different.
Share Button
New comment
Comments
No comments for this article
References
1. Bennett C, Moayyedi P, Corley DA, DeCaestecker J, Falck-Ytter Y, Falk G, et al. BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. Am J Gastroenterol 2015 May;110(5):662-82.
2. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014; 63:7–42.
3. Peters FP, Curvers WL, Rosmolen WD, de Vries CE, Ten Kate FJ, Krishnadath KK. Surveillance history of endoscopically treated patients with early Barrett's neoplasia: nonadherence to the Seattle biopsy protocol leads to sampling error. Dis Esophagus 2008;21(6):475-9.
4. Desai TK, Krishnan K, Samala N, Singh J, Cluley J, Perla S et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut 2012;61(7):970-6.
6. Singh S, Manickam P, Amin AV, Samala N, Schouten LJ, Iyer PG et al. Incidence of esophageal adenocarcinoma in Barrett's esophagus with low-grade dysplasia: a systematic review and meta-analysis.Gastrointest Endosc 2014;79(6):897-909.
7. Parrilla P, Ortiz A, Martinez de Haro LF, Aguayo JL, Ramirez P. Evaluation of the magnitude of gastro-oesophageal reflux in Barrett's oesophagus. Gut 1990 Sep;31(9):964-7.
8. Pera M, Pera M. Experimental Barrett's esophagus and the origin of intestinal metaplasia. Chest Surg Clin N Am 2002;12(1):25-37.
9. Bechi P, Pucciani F, Baldini F, Cosi F, Falciai R, Mazzanti R et al. Long-term ambulatory enterogastric reflux monitoring. Validation of a new fiberoptic technique. Dig Dis Sci 1993;38(7):1297-306.
10. Martinez de Haro L, Ortiz A, Parrilla P, Munitiz V, Molina J, Bermejo J et al. Intestinal metaplasia in patients with columnar lined esophagus is associated with high levels of duodenogastroesophageal reflux. Ann Surg 2001;233(1):34-8.
11. Parrilla P, Liron R, Martinez de Haro LF, Ortiz A, Molina J, De Andrés B. Gastric surgery does not increase the risk of developing Barrett's esophagus. Am J Gastroenterol 1997;92(6):960-3.
12. Munitiz V, Parrilla P, Ortiz A, Martinez de Haro LF, Yelamos J, Molina J. High risk of malignancy in familial Barrett's esophagus: presentation of one family. J Clin Gastroenterol 2008;42(7):806-9.
13. Drovdlic CM, Goddard KA, Chak A, Brock W, Chessler L, King JF et al. Demographic and phenotypic features of 70 families segregating Barrett's oesophagus and oesophageal adenocarcinoma. J Med Genet 2003;40(9):651-6.
14. Chak A, Lee T, Kinnard MF, Brock W, Faulx A, Willis J et al. Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults.Gut 2002;51(3):323-8.
15. Chak A, Ochs-Balcom H, Falk G, Grady WM, Kinnard M, Willis JE et al. Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. Cancer Epidemiol Biomarkers Prev 2006; 15(9):1668-73.
16. Fecteau RE, Kong J, Kresak A, Brock W, Song Y, Fujioka H et al. Association between germline mutation in VSIG10L and Familial Barrett neoplasia. JAMA Oncol 2016; 2(10): 1333–9.
17. Feber A, Xi L, Luketich JD, Pennathur A, Landreneau RJ, Wu M et al. MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg 2008; 135(2): 255–60.
18. Revilla-Nuin B, Parrilla P, Lozano JJ, de Haro LF, Ortiz A, Martínez C et al. Predictive value of MicroRNAs in the progression of Barrett esophagus to adenocarcinoma in a long-term follow-up study. Ann Surg 2013;257(5):886-93.
19. Peters JH. Barrett's esophagus: now what?. Ann Surg 2003;237(3):299-300.
20. Spechler SJ, Lee E, Ahnen D, Goyal RK, Hirano I, Ramirez F et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001;285(18):2331-8.
21. Ortiz A, Martinez de Haro LF, Parrilla P, Morales G, Molina J, Bermejo J et al. Conservative treatment versus antireflux surgery in Barrett's oesophagus: long-term results of a prospective study. Br J Surg 1996;83(2):274-8.
22. Parrilla P, Martínez de Haro LF, Ortiz A, Munitiz V, Molina J et al. Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett’s Esophagus. Ann Surg 2003; 237(3): 291–8.
23. Maret-Ouda J, Konings P, Lagergren J, Brusselaers N. Antireflux surgery and risk of esophageal adenocarcinoma: a systematic review and meta-analysis. Ann Surg 2016;263(2):251-7.
24. Haidry RJ, Dunn JM, Butt MA, Burnell MG, Gupta A, Green S et al. Radiofrequency ablation and endoscopic mucosal resection for dysplastic Barrett's esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry. Gastroenterology 2013;145(1):87-95.
25. Blot WJ, Tarone RE. Doll and Peto's quantitative estimates of cancer risks: holding generally true for 35 years. J Natl Cancer Inst. 2015 Mar 3;107(4).
5. Arroyo-Martinez Q, Rodriguez-Tellez M, Garcia-Escudero A, Brugal-Medina J, Gonzalez-Campora R, Caunedo Alvarez A. Epidemiology of Barrett's esophagus and esophageal adenocarcinoma in Spain. A unicentric study. Rev Esp Enferm Dig 2016;108(10):609-17.
Citation tools
Munitiz Ruiz V, Martienz de Haro L, Ortiz Á, Ruiz de Angulo D, Parrilla P. Barrett’s esophagus: “All diseases are divine and all are human”. 6261/2019


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1247 visits.
This article has been downloaded 352 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 04/03/2019

Accepted: 15/04/2019

Online First: 25/09/2019

Published: 03/10/2019

Article revision time: 35 days

Article Online First time: 205 days

Article editing time: 213 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology